vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and DNA X, Inc. (SONM). Click either name above to swap in a different company.
AGIOS PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($20.0M vs $16.2M, roughly 1.2× DNA X, Inc.). DNA X, Inc. runs the higher net margin — -29.3% vs -541.1%, a 511.8% gap on every dollar of revenue. On growth, AGIOS PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (86.1% vs 7.9%). Over the past eight quarters, AGIOS PHARMACEUTICALS, INC.'s revenue compounded faster (56.1% CAGR vs 9.9%).
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
AGIO vs SONM — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.0M | $16.2M |
| Net Profit | $-108.0M | $-4.8M |
| Gross Margin | 90.6% | 11.2% |
| Operating Margin | -608.9% | -24.5% |
| Net Margin | -541.1% | -29.3% |
| Revenue YoY | 86.1% | 7.9% |
| Net Profit YoY | -11.9% | -89.2% |
| EPS (diluted) | $-1.86 | $-4.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.0M | — | ||
| Q3 25 | $12.9M | $16.2M | ||
| Q2 25 | $12.5M | $11.2M | ||
| Q1 25 | $8.7M | $16.7M | ||
| Q4 24 | $10.7M | $15.3M | ||
| Q3 24 | $9.0M | $15.0M | ||
| Q2 24 | $8.6M | $11.5M | ||
| Q1 24 | $8.2M | $9.1M |
| Q4 25 | $-108.0M | — | ||
| Q3 25 | $-103.4M | $-4.8M | ||
| Q2 25 | $-112.0M | $-7.5M | ||
| Q1 25 | $-89.3M | $458.0K | ||
| Q4 24 | $-96.5M | $-21.6M | ||
| Q3 24 | $947.9M | $-2.5M | ||
| Q2 24 | $-96.1M | $-6.6M | ||
| Q1 24 | $-81.5M | $-2.9M |
| Q4 25 | 90.6% | — | ||
| Q3 25 | 87.0% | 11.2% | ||
| Q2 25 | 86.3% | 7.6% | ||
| Q1 25 | 87.6% | 50.0% | ||
| Q4 24 | 88.3% | -1.2% | ||
| Q3 24 | 91.3% | 28.2% | ||
| Q2 24 | 82.6% | 25.8% | ||
| Q1 24 | 92.3% | 31.8% |
| Q4 25 | -608.9% | — | ||
| Q3 25 | -907.4% | -24.5% | ||
| Q2 25 | -1020.1% | -60.2% | ||
| Q1 25 | -1222.0% | 3.9% | ||
| Q4 24 | -1165.3% | 55.3% | ||
| Q3 24 | -1146.9% | -15.8% | ||
| Q2 24 | -1228.3% | -56.2% | ||
| Q1 24 | -1124.3% | -29.5% |
| Q4 25 | -541.1% | — | ||
| Q3 25 | -803.1% | -29.3% | ||
| Q2 25 | -899.4% | -66.8% | ||
| Q1 25 | -1023.3% | 2.7% | ||
| Q4 24 | -899.6% | -141.6% | ||
| Q3 24 | 10574.7% | -16.7% | ||
| Q2 24 | -1115.7% | -57.5% | ||
| Q1 24 | -995.8% | -31.9% |
| Q4 25 | $-1.86 | — | ||
| Q3 25 | $-1.78 | $-4.83 | ||
| Q2 25 | $-1.93 | $-0.79 | ||
| Q1 25 | $-1.55 | $0.08 | ||
| Q4 24 | $-1.44 | $-116.99 | ||
| Q3 24 | $16.22 | $-9.32 | ||
| Q2 24 | $-1.69 | $-1.41 | ||
| Q1 24 | $-1.45 | $-0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.1M | $2.1M |
| Total DebtLower is stronger | — | $5.1M |
| Stockholders' EquityBook value | $1.2B | $-701.0K |
| Total Assets | $1.3B | $40.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.1M | — | ||
| Q3 25 | $92.7M | $2.1M | ||
| Q2 25 | $80.9M | $2.0M | ||
| Q1 25 | $79.0M | $2.1M | ||
| Q4 24 | $76.2M | $5.3M | ||
| Q3 24 | $253.7M | $9.1M | ||
| Q2 24 | $84.5M | $9.6M | ||
| Q1 24 | $118.8M | $9.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $2.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.3B | $-701.0K | ||
| Q2 25 | $1.4B | $-1.3M | ||
| Q1 25 | $1.5B | $-1.1M | ||
| Q4 24 | $1.5B | $-5.7M | ||
| Q3 24 | $1.6B | $15.3M | ||
| Q2 24 | $660.5M | $17.5M | ||
| Q1 24 | $743.9M | $19.8M |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.4B | $40.2M | ||
| Q2 25 | $1.5B | $36.1M | ||
| Q1 25 | $1.6B | $36.0M | ||
| Q4 24 | $1.7B | $39.7M | ||
| Q3 24 | $1.8B | $49.1M | ||
| Q2 24 | $773.1M | $45.9M | ||
| Q1 24 | $849.7M | $42.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-96.2M | $-7.0M |
| Free Cash FlowOCF − Capex | $-97.3M | — |
| FCF MarginFCF / Revenue | -487.5% | — |
| Capex IntensityCapex / Revenue | 5.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-377.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-96.2M | — | ||
| Q3 25 | $-88.2M | $-7.0M | ||
| Q2 25 | $-77.1M | $-4.9M | ||
| Q1 25 | $-111.5M | $-9.6M | ||
| Q4 24 | $-133.2M | $-4.5M | ||
| Q3 24 | $-84.2M | $-417.0K | ||
| Q2 24 | $-72.6M | $-3.4M | ||
| Q1 24 | $-99.9M | $-168.0K |
| Q4 25 | $-97.3M | — | ||
| Q3 25 | $-89.7M | — | ||
| Q2 25 | $-78.0M | — | ||
| Q1 25 | $-112.3M | — | ||
| Q4 24 | $-134.1M | $-4.5M | ||
| Q3 24 | $-84.6M | $-554.0K | ||
| Q2 24 | $-72.7M | $-3.4M | ||
| Q1 24 | $-100.0M | $-198.0K |
| Q4 25 | -487.5% | — | ||
| Q3 25 | -696.5% | — | ||
| Q2 25 | -626.2% | — | ||
| Q1 25 | -1286.4% | — | ||
| Q4 24 | -1250.1% | -29.6% | ||
| Q3 24 | -944.2% | -3.7% | ||
| Q2 24 | -844.4% | -29.8% | ||
| Q1 24 | -1221.2% | -2.2% |
| Q4 25 | 5.6% | — | ||
| Q3 25 | 12.1% | — | ||
| Q2 25 | 7.0% | — | ||
| Q1 25 | 8.8% | — | ||
| Q4 24 | 9.0% | 0.1% | ||
| Q3 24 | 4.7% | 0.9% | ||
| Q2 24 | 1.8% | 0.3% | ||
| Q1 24 | 1.7% | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -20.97× | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.09× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
